IL22 and graft versus host disease: The same research group has demonstrated that daily administration of IL-22 for 3 weeks starting 1 week post-transplantation increases the survival and function of host radio-resistant ILC3s, subsequently reducing apoptosis in host intestinal stem cells and reducing GVHD severity through preservation of host cells from damage without compromising immune function or reconstitution (275).